Prostatic Neoplasms, Castration-Resistant Clinical Trials

10 recruiting

Prostatic Neoplasms, Castration-Resistant Trials at a Glance

10 actively recruiting trials for prostatic neoplasms, castration-resistant are listed on ClinicalTrialsFinder across 6 cities in 27 countries. The largest study group is Phase 1 with 7 trials, with the heaviest enrollment activity in Madrid, New York, and Barcelona. Lead sponsors running prostatic neoplasms, castration-resistant studies include Celcuity Inc, Clarity Pharmaceuticals Ltd, and Cancer Research UK.

Browse prostatic neoplasms, castration-resistant trials by phase

Treatments under study

About Prostatic Neoplasms, Castration-Resistant Clinical Trials

Looking for clinical trials for Prostatic Neoplasms, Castration-Resistant? There are currently 10 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Prostatic Neoplasms, Castration-Resistant trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Prostatic Neoplasms, Castration-Resistant clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting
Phase 1Phase 2

Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)

Prostatic Neoplasms, Castration-Resistant
Merck Sharp & Dohme LLC220 enrolled77 locationsNCT06353386
Recruiting
Phase 3

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

Prostatic Neoplasms, Castration-Resistant
Janssen Research & Development, LLC800 enrolled97 locationsNCT07225946
Recruiting
Phase 1Phase 2

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

Prostate CancermCRPC (Metastatic Castration-resistant Prostate Cancer)Prostatic Neoplasms, Castration-Resistant+3 more
Celcuity Inc54 enrolled13 locationsNCT06190899
Recruiting
Phase 1Phase 2

64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)

Prostatic Neoplasms, Castration-Resistant
Clarity Pharmaceuticals Ltd54 enrolled7 locationsNCT04868604
Recruiting
Phase 1

Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer

Prostatic Neoplasms, Castration-Resistant
Weill Medical College of Cornell University30 enrolled1 locationNCT05743621
Recruiting
Phase 1Phase 2

HTL0039732 in Participants With Advanced Solid Tumours

SarcomaUrinary Bladder NeoplasmsUterine Cervical Neoplasms+11 more
Cancer Research UK150 enrolled5 locationsNCT05944237
Recruiting
Phase 1Phase 2

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Endometrial CancerAdvanced Solid TumorDiffuse Large B Cell Lymphoma+5 more
Novartis Pharmaceuticals275 enrolled60 locationsNCT04104776
Recruiting
Phase 1

Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer

Prostatic Neoplasms, Castration-Resistant
Endocyte99 enrolled2 locationsNCT04597411
Recruiting
Phase 4

18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer

NeoplasmsMetastatic Prostate CancerNeoplasms by Site+8 more
VA Greater Los Angeles Healthcare System15 enrolled1 locationNCT06706921
Recruiting
Phase 2

Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC

Prostatic Neoplasms, Castration-Resistant
Leiden University Medical Center168 enrolled19 locationsNCT05393791